O
Oana Petrenciuc
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 37
Citations - 1961
Oana Petrenciuc is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Breast cancer & Sorafenib. The author has an hindex of 17, co-authored 37 publications receiving 1648 citations. Previous affiliations of Oana Petrenciuc include Bayer Corporation & Bayer.
Papers
More filters
Journal ArticleDOI
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
Michael J. Moore,Hal W. Hirte,L.L. Siu,Amit M. Oza,Sebastien J. Hotte,Oana Petrenciuc,F. Cihon,Chetan Lathia,Brian Schwartz +8 more
TL;DR: Results indicate that further clinical investigation of BAY 43--9006 is warranted, and suggest it could be a promising future therapy for patients with cancer.
Journal ArticleDOI
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad,Joan Carles,Silke Gillessen,Axel Heidenreich,Daniel Heinrich,Jeremy Gratt,Jeremy Levy,Kurt Miller,Sten Nilsson,Oana Petrenciuc,Marcello Tucci,Manfred P. Wirth,Judith Federhofer,Joe M. O'Sullivan +13 more
TL;DR: This study investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radia-223, an international, prospective, interventional, open-label, single-arm, phase 3b study.
Journal ArticleDOI
Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma
Christine Elser,Lillian L. Siu,Eric Winquist,Mark Agulnik,Gregory R. Pond,Soo Chin,Peggy Francis,Robin Cheiken,James Elting,Angela McNabola,Dean Wilkie,Oana Petrenciuc,Eric Chen +12 more
TL;DR: Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients, and further development in combination with radiation or other agents may be warranted.
Journal ArticleDOI
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Karim Fizazi,Neal D. Shore,Teuvo L Tammela,Albertas Ulys,Egils Vjaters,Sergey Polyakov,Mindaugas Jievaltas,M. Luz,Boris Alekseev,Iris Kuss,Marie-Aude Le Berre,Oana Petrenciuc,Amir Snapir,Toni Sarapohja,Matthew R. Smith,Aramis Investigators +15 more
TL;DR: Among men with nonmetastatic, castration-resistant prostate cancer, the percentage of patients who were alive at 3 years was significantly higher among those who received darolutamide than amongThose who received placebo, and Darolutamia was also associated with a significant benefit with respect to all other secondary end points.
Journal ArticleDOI
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Lillian L. Siu,Ahmad Awada,Chris H. Takimoto,Martine Piccart,Brian Schwartz,Tom Giannaris,Chetan Lathia,Oana Petrenciuc,Malcolm J. Moore +8 more
TL;DR: Sorafenib and gemcitabine are well tolerated in combination; further evaluations in pancreatic and ovarian cancers are warranted.